Key Clinical Message:
Elucidating the mechanisms of inactivating mutations of SIRT1 to
the tumor suppressor genes p53 and p16 in Bowen’s disease
may not only help to clarify the oncogenic mechanisms but also lead to
the development of new molecular targeted therapies.